|45.65|| +1.35 / +3.05%|
Supernus Pharmaceuticals, Inc. develops and commercializes products for the treatment of central nervous system. It also develops multiple product candidates in psychiatry to address the large market opportunity in the treatment of attention deficit hyperactivity disorder, or ADHD, including ADHD patients with impulsive aggression. The company markets their products in the U.S. through their own focused sales force targeting specialty physicians and seek strategic collaborations with other pharmaceutical companies to license their products outside the U.S. Its neurology portfolio consists of Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended release topiramate). The company's psychiatry product candidates include SPN-810 (molindone hydrochloride), SPN-812 and SPN-809. Supernus Pharmaceuticals was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
|Jack A. Khattar||President, CEO, Secretary & Director|
|Gregory S. Patrick||CFO, Vice President & Head-Investor Relations|
|Padmanabh P. Bhatt||Chief Scientific Officer & Senior Vice President|
|Stefan K. F. Schwabe||Chief Medical Officer, EVP-Research & Development|
|Bryan A. Roecklein||Vice President-Corporate Development|